Cipla Ltd on Thursday announced that its wholly owned subsidiary, Invagen Pharmaceuticals Inc, has entered into a strategic partnership with Qilu Pharmaceutical to license and supply a biosimilar of the cancer drug Keytruda in the United States.
The product, QL2107, is a biosimilar of pembrolizumab (Keytruda) and is aimed at expanding access to advanced cancer treatments while helping reduce treatment costs, Cipla said in a regulatory filing.
Under the partnership, Qilu will oversee the product's development, regulatory registration and supply, while Cipla will use its commercial presence in the US to market the asset.